Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL versus SULFAMETHOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL versus SULFAMETHOXAZOLE.
GANTANOL vs SULFAMETHOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
800 mg orally every 12 hours for 5-7 days.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults; prolonged in renal impairment (up to 24-36 hours in CrCl <30 mL/min).
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Trovafloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfamethoxazole + Nalidixic acid
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Renal: 70% as unchanged drug; hepatic metabolism: 20% (glucuronidation); fecal: 10%.
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Category C
Category D/X
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Nalidixic acid."